Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ablynx NV stock logo
ABLYF
Ablynx
$50.63
$50.63
$12.50
$55.04
$3.81B1.995,063 shsN/A
Genmab A/S stock logo
GMAB
Genmab A/S
$21.32
+0.6%
$19.84
$17.24
$28.96
$13.65B1.041.13 million shs261,946 shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$209.75
-0.2%
$196.07
$170.00
$292.80
$13.86B1.022,875 shs61 shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.86
$64.72
$131.98
$14.05B0.691.53 million shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ablynx NV stock logo
ABLYF
Ablynx
0.00%0.00%0.00%0.00%0.00%
Genmab A/S stock logo
GMAB
Genmab A/S
-0.42%+3.27%+2.71%-6.78%-24.35%
Genmab A/S stock logo
GNMSF
Genmab A/S
-0.17%+0.67%+2.71%-7.57%-27.66%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%+2.82%+100.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
3.4025 of 5 stars
3.33.00.00.02.80.03.1
Genmab A/S stock logo
GNMSF
Genmab A/S
0.2646 of 5 stars
0.01.00.00.01.90.01.3
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.6534 of 5 stars
1.10.00.04.50.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ablynx NV stock logo
ABLYF
Ablynx
0.00
N/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
2.69
Moderate Buy$39.1784.31% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
0.00
N/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside

Current Analyst Ratings Breakdown

Latest ABLYF, GNMSF, ITCI, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
Genmab A/S stock logo
GMAB
Genmab A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $37.00
4/2/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00
4/1/2025
Genmab A/S stock logo
GMAB
Genmab A/S
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform
3/11/2025
Genmab A/S stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $45.00
3/11/2025
Genmab A/S stock logo
GMAB
Genmab A/S
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ablynx NV stock logo
ABLYF
Ablynx
$62.73M60.74N/AN/A$2.71 per share18.68
Genmab A/S stock logo
GMAB
Genmab A/S
$3.12B4.37$1.44 per share14.80$8.04 per share2.64
Genmab A/S stock logo
GNMSF
Genmab A/S
$3.12B4.44$14.28 per share14.69$80.53 per share2.60
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ablynx NV stock logo
ABLYF
Ablynx
-$122.67MN/A0.00N/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
$1.14B$1.7612.2611.942.6536.30%16.78%13.79%8/14/2025 (Estimated)
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.14B$17.6311.97N/A36.30%19.75%16.23%8/7/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A

Latest ABLYF, GNMSF, ITCI, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Genmab A/S stock logo
GMAB
Genmab A/S
$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million
5/8/2025Q1 2025
Genmab A/S stock logo
GNMSF
Genmab A/S
$1.88$3.05+$1.17$3.05$761.09 million$765.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
5.25
5.24
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
5.25
5.24
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51

Institutional Ownership

CompanyInstitutional Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%

Insider Ownership

CompanyInsider Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ablynx NV stock logo
ABLYF
Ablynx
N/A75.25 millionN/ANot Optionable
Genmab A/S stock logo
GMAB
Genmab A/S
1,660641.20 million651.58 millionOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
1,66066.08 million65.06 millionNot Optionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable

Recent News About These Companies

JnJ closes Intra-Cellular Therapies acquisition
Intra-Cellular Therapies
Intra-Cellular downgraded to Neutral from Outperform at Mizuho
Financial markets news icon
MarketBeat Week in Review – 01/13 - 01/17 (ITCI)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ablynx stock logo

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)
As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$21.32 +0.13 (+0.60%)
As of 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S stock logo

Genmab A/S OTCMKTS:GNMSF

$209.75 -0.37 (-0.17%)
As of 05/28/2025 02:50 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.